A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
NCT #
NCT05983432
Condition(s)
Lung Cancer (NSCLC), Solid Tumor
Molecular Target(s)
EGFR, HER3
Drug Classification(s)
Antibody Drug Conjugate, Bispecific Antibodies
Agents(s)
BL-B01D1
Phase(s)
I
Mechanism of Action
EGFR x HER3 bispecific antibody-drug conjugate
Purpose
- How much of BL-B01D1 can be given with an acceptable level of side effects
- The effects of BL-B01D1 (good and bad)
- How much of BL-B01D1 is absorbed into the blood and how fast it is removed
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.